Jared Kaltwasser

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

A teledermatology program in Georgia helped identify patients with skin lesions that warranted in-person follow-up with a physician.

The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by artificial intelligence, but the drug’s target itself was, too.

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

A new analysis of obesity guidelines suggests more evidence is needed to develop stronger guidelines for the transition period between childhood and adulthood.

Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.

A new report suggests a noninvasive means to evaluate portal hypertension in patients with BCR::ABL1-negative myeloproliferative neoplasms.

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line autologous stem cell transplant (auto-SCT).

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with large B-cell lymphoma.

A new analysis suggests artificial intelligence algorithms are able to accurately assess lesion severity in patients with atopic dermatitis.

People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of the pandemic, a Swedish study found.

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

The findings highlight the limits of risk stratification algorithms based on data from older patients.

New findings suggest that reducing the variant allele frequency of JAK2V617F should be a goal of treatment for polycythemia vera.

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the need for targeted treatment strategies.

The tool could make it easier for clinicians to rule out melanoma without the need for excision.

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary hypertension.

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

Two studies explored the quality-of-life impacts of lebrikizumab for atopic dermatitis, finding its benefits extend beyond physical symptom improvements.

Clinical trials for idiopathic pulmonary fibrosis could benefit from improved patient engagement to include diverse perspectives and inclusive practices.

Individuals with rheumatoid arthritis face a higher risk of hospitalization for heart failure and pulmonary edema, a new report found.

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Forced oscillation technique (FOT) can enhance early detection and management of progressive pulmonary fibrosis.

Machine learning identifies key biomarkers predicting hydroxyurea resistance in polycythemia vera, enhancing early treatment strategies and patient outcomes.

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.